Trump's CMS signals flexibility on Medicare drug price negotiation, sparking new questions for RFK Jr.
The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process of negotiating prices for certain Medicare Part D drugs with input f | The agency said it is "considering opportunities to bring greater transparency" and will consider stakeholder feedback on the program.
Trump's administration aims for 'greater transparency' in drug price negotiations
The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under President Donald Trump's administration following criticism from the pharmaceutical industry for the Biden-era law.
Many independent pharmacists will not stock drugs in the price negotiation program
According to the survey cited by NCPA, 60.4% of independent pharmacists are considering not stocking one or more of the first 10 drugs, while 32.8% have already decided not to. More than 96% said PBM and plan reimbursement for Medicare Part D threatened the viability of their business.
Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
US govt looks to bring 'greater transparency' in Medicare drug price negotiations
The U.S. government said on Wednesday it will consider opportunities to "bring greater transparency" for the Medicare drug price negotiation program under President Donald Trump's administration. The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.
Cardiometabolic drugs consume majority of cost among those up for price negotiation
Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications consumed more than 80% of Medicare Part D spending, researchers reported.Delayed negotiations may incur significant excess federal spending,
Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations
The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.
Trump administration affirms drug price talks, but will seek input to ‘improve’ program
A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more transparent.
‘We applaud CMS’: Two more rheumatology drugs bound for Medicare price negotiation
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — a move applauded by experts as they await the impact of the first-round of discounts anticipated next year.
Morningstar2d
New Analysis Finds the Medicare Drug Price Negotiation Program Threatens Financial Stability of American Pharmacies
NCPA calls for immediate freeze of Medicare Drug Price Negotiation to protect pharmacies and patients Today, the National Community Pharmacists Association released a first-of-its-kind analysis ...
STAT11d
Medicare drug price negotiations need something new: a floor
Soon, the Centers for Medicare and Medicaid Services will begin the price negotiation process on a new set of 15 drugs. The new Trump administration should seize the opportunity to change the ...